5,841 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Fieldview Capital Management LLC

Fieldview Capital Management LLC acquired a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in the 4th quarter, Holdings Channel reports. The fund acquired 5,841 shares of the company’s stock, valued at approximately $510,000.

Several other large investors have also made changes to their positions in the business. Smartleaf Asset Management LLC lifted its position in shares of Protagonist Therapeutics by 11.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,403 shares of the company’s stock worth $91,000 after purchasing an additional 146 shares during the last quarter. Farther Finance Advisors LLC lifted its position in shares of Protagonist Therapeutics by 110.6% during the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after purchasing an additional 156 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its position in shares of Protagonist Therapeutics by 1.5% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 13,393 shares of the company’s stock worth $1,170,000 after purchasing an additional 193 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Protagonist Therapeutics by 8.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,959 shares of the company’s stock valued at $258,000 after acquiring an additional 221 shares during the period. Finally, Parkman Healthcare Partners LLC increased its stake in Protagonist Therapeutics by 0.4% during the third quarter. Parkman Healthcare Partners LLC now owns 61,849 shares of the company’s stock valued at $4,109,000 after acquiring an additional 253 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

Insider Buying and Selling

In other news, Director William D. Waddill sold 9,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $107.68, for a total value of $969,120.00. Following the sale, the director directly owned 7,825 shares in the company, valued at approximately $842,596. This represents a 53.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Asif Ali sold 1,750 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $105.47, for a total value of $184,572.50. Following the completion of the sale, the chief financial officer owned 59,003 shares in the company, valued at approximately $6,223,046.41. This represents a 2.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 272,345 shares of company stock worth $27,676,386. Insiders own 5.19% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Truist Financial boosted their price target on Protagonist Therapeutics from $110.00 to $121.00 and gave the company a “buy” rating in a research note on Tuesday, April 14th. Wolfe Research assumed coverage on Protagonist Therapeutics in a research note on Thursday, May 21st. They set an “outperform” rating and a $135.00 price target on the stock. Barclays boosted their price target on Protagonist Therapeutics from $113.00 to $119.00 and gave the company an “overweight” rating in a research note on Thursday, March 19th. Weiss Ratings restated a “sell (d+)” rating on shares of Protagonist Therapeutics in a research note on Friday, May 15th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $110.00 price target on shares of Protagonist Therapeutics in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Protagonist Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $115.21.

Protagonist Therapeutics Stock Up 2.4%

Shares of PTGX opened at $112.46 on Tuesday. Protagonist Therapeutics, Inc. has a 12-month low of $49.38 and a 12-month high of $112.77. The firm has a market capitalization of $7.23 billion, a price-to-earnings ratio of -62.13 and a beta of 1.86. The stock’s 50-day moving average price is $101.89 and its 200 day moving average price is $93.42.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.55. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%.The company had revenue of $56.37 million for the quarter, compared to analyst estimates of $11.70 million. Equities research analysts expect that Protagonist Therapeutics, Inc. will post 2.93 EPS for the current year.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.